Wells Fargo & Company Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $72.00

Definium Therapeutics (NASDAQ:DFTX) had its price target raised by equities researchers at Wells Fargo & Company from $68.00 to $72.00 in a report released on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 68.26% from the company’s previous close.

DFTX has been the subject of several other research reports. Robert W. Baird lifted their price target on Definium Therapeutics from $57.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday. JonesTrading increased their price objective on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, June 24th. Oppenheimer restated an “outperform” rating and set a $70.00 price objective on shares of Definium Therapeutics in a research note on Wednesday. Stifel Nicolaus upped their target price on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Finally, Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $58.69.

Definium Therapeutics Price Performance

DFTX stock opened at $42.79 on Thursday. Definium Therapeutics has a twelve month low of $8.70 and a twelve month high of $49.70. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a market cap of $4.27 billion, a PE ratio of -12.48 and a beta of 2.23. The business has a 50 day moving average of $39.06 and a 200 day moving average of $26.52.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, research analysts forecast that Definium Therapeutics will post -2.81 EPS for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the transaction, the insider owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert Barrow sold 29,208 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the sale, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. This represents a 2.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 48,096 shares of company stock valued at $2,165,763. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. grew its position in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares during the period. BNP Paribas Financial Markets raised its holdings in Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after purchasing an additional 3,020 shares during the period. Caxton Associates LLP purchased a new position in Definium Therapeutics during the third quarter valued at $126,000. Mercer Global Advisors Inc. ADV grew its holdings in Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after purchasing an additional 2,079 shares during the period. Finally, Scientech Research LLC bought a new stake in Definium Therapeutics during the third quarter valued at about $286,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported positive topline results from its Phase 3 Voyage study. DT120 ODT produced a 5.4-point improvement versus placebo on the Hamilton Anxiety Rating Scale, supporting the drug’s efficacy in GAD. Definium says LSD-based pill reduces anxiety in late-stage study
• Positive Sentiment: The results represent the second positive Phase 3 study for DT120, increasing confidence in the treatment’s potential across indications and driving significant investor interest. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: Robert W. Baird raised its price target from $57 to $75 and kept an “outperform” rating. Needham also lifted its target from $50 to $66 and assigned a “buy” rating, signaling greater analyst confidence in DFTX’s pipeline and valuation. Analyst price-target changes
• Neutral Sentiment: Trading in DFTX was briefly halted for “news pending” before the Phase 3 announcement, reflecting the market sensitivity surrounding the clinical update.
• Negative Sentiment: HC Wainwright reduced its 2026 and 2027 EPS forecasts and lowered longer-term estimates, including FY2028 through FY2030. The revisions indicate expectations for continued losses and potentially slower profitability, although this concern was outweighed by the clinical data.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.